Current location - Education and Training Encyclopedia - Graduation thesis - Brief Introduction of the Author of Pathological Diagnosis of Breast Tumors
Brief Introduction of the Author of Pathological Diagnosis of Breast Tumors
Fu Xilin, 1936 was born in Longchuan County, Guangdong Province in May. 1959 graduated from the Department of Medicine of Hebei Medical College, 1964 studied under the famous tumor pathologist Professor Wang Deyan, 1985 devoted himself to the pathological diagnosis and research of breast tumors. At present, he is a professor and chief physician of the Cancer Hospital affiliated to Tianjin Medical University, and the director of the Breast Cancer Research Office of the Cancer Institute. Special government allowance granted by the State Council; 1994 was included in the dictionary of world celebrities in Cambridge, England; He is also a member of the Standing Committee of Breast Cancer Professional Committee of China Anti-Cancer Association, a member of Tumor Metastasis Professional Committee, the editorial board of China Cancer Clinic and the editorial board of Chinese chinese journal of clinical and experimental pathology. Up to now, he has published more than 70 academic papers, edited the ninth volume Pathological Types of Breast Tumors of China Classification of Tumor Pathology, and participated in the compilation of monograph 14, including Breast Cancer Volume, Oncology, Tumor Pathology, Tumor Pathology by Wang Deyan, and Breast Oncology. In China, it took the lead in carrying out the research on continuous sections of negative lymph nodes in routine pathological examination of breast cancer, the research on subcontinuous large sections of breast cancer and the application of anti-human breast cancer monoclonal antibody M4C3 to distinguish lymph node metastasis of recessive breast cancer, and participated in the national "Ninth Five-Year Plan" key project breast cancer research project; Before my employment, I presided over the prospective pathological study of multiple primary lesions of primary adenocarcinoma and the multi-index pathological study of breast cancer in China, both of which won the Tianjin Science and Technology Progress Award.